Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka

Jan 30 2012

• By Wendy Diller

Related Content

Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib

Feb 16 2011

Astellas Wins OSI But Victory Comes At A Price

Jun 01 2010

Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets

May 13 2011

Astellas Pays, And Pays Big, To Extend VelocImmune License With Regeneron

Jul 28 2010

Related Companies

OSI Systems, Inc.

Astellas Pharma, Inc.

MorphoSys AG

Regeneron Pharmaceuticals, Inc.

Medivation, Inc.

AVEO Pharmaceuticals, Inc.

Astellas Pharma, Inc.

Onyx Pharmaceuticals, Inc.

Bayer AG

AstraZeneca PLC

Royalty Pharma plc

Innoviva, Inc.

Additional Topics

Japan Asia Pacific United States Strategy Business Strategies Clinical Trials BioPharmaceutical

More from Japan

More from Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window